Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 11/20 | 0.56 |
| ▸ | EDNRB | P24530 | 9/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5330400 | 1.00 | EDNRA (0.56) | EDNRAEDNRBBRD4FBP1ALDH1A1 | |
| SCHEMBL30171185 | 0.86 | EDNRA (0.63) | EDNRAEDNRBBRD4 | |
| SCHEMBL5529599 | 0.86 | EDNRA (0.63) | EDNRAEDNRBBRD4 | |
| SCHEMBL30296336 | 0.84 | EDNRA (0.56) | EDNRAEDNRBBRD4FBP1 | |
| SCHEMBL5321684 | 0.84 | EDNRA (0.56) | EDNRAEDNRBBRD4FBP1 | |
| SCHEMBL29281015 | 0.83 | EDNRA (0.45) | EDNRAEDNRB | |
| SCHEMBL30296058 | 0.82 | EDNRA (0.66) | EDNRAEDNRBFBP1 | |
| SCHEMBL7222597 | 0.80 | EDNRB (0.61) | EDNRAEDNRBBRD4ALDH1A1RXFP1 | |
| SCHEMBL9063934 | 0.80 | EDNRB (0.61) | EDNRAEDNRBBRD4ALDH1A1RXFP1 | |
| SCHEMBL24822840 | 0.80 | EDNRA (0.43) | EDNRAEDNRBALDH1A1RXFP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051315-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION | ALCHEMEDICINE, INC. (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4458826-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION | Alchemedicine, Inc. (JP) | 2024-11-06 | — | — | EP | disclosed |
| CN-118546134-A | Crystal form containing aromatic ring derivative antagonist, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118284605-A | Compounds, angiotensin II type 1 receptor antagonists and pharmaceutical compositions | 亚克医药株式会社 | 2024-07-02 | — | — | CN | disclosed |
| CN-117836294-A | Biological antagonist containing aromatic ring, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051315-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION | AGTR1, AGTR2, ADRB1 | EDNRA 154/4885EDNRB 216/4885BRD4 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.